These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
889 related articles for article (PubMed ID: 25966677)
1. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Miller-Kleinhenz JM; Bozeman EN; Yang L Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677 [TBL] [Abstract][Full Text] [Related]
2. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412 [TBL] [Abstract][Full Text] [Related]
3. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724 [TBL] [Abstract][Full Text] [Related]
4. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. Devulapally R; Sekar NM; Sekar TV; Foygel K; Massoud TF; Willmann JK; Paulmurugan R ACS Nano; 2015 Mar; 9(3):2290-302. PubMed ID: 25652012 [TBL] [Abstract][Full Text] [Related]
5. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK; Singh A; Ganta S; Amiji MM Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in nanotheranostics for triple negative breast cancer treatment. Thakur V; Kutty RV J Exp Clin Cancer Res; 2019 Oct; 38(1):430. PubMed ID: 31661003 [TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158 [TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
9. Nanosoldiers: A promising strategy to combat triple negative breast cancer. Pawar A; Prabhu P Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766 [TBL] [Abstract][Full Text] [Related]
10. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625 [TBL] [Abstract][Full Text] [Related]
11. Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives. Bazzazan MA; Fattollazadeh P; Keshavarz Shahbaz S; Rezaei N Int J Pharm; 2024 Oct; 664():124639. PubMed ID: 39187034 [TBL] [Abstract][Full Text] [Related]
12. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles. Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300 [TBL] [Abstract][Full Text] [Related]
13. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Guo P; Yang J; Huang J; Auguste DT; Moses MA Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668 [TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Shapira A; Livney YD; Broxterman HJ; Assaraf YG Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184 [TBL] [Abstract][Full Text] [Related]
16. Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple-Negative Breast Cancer Treatment. Torres Quintas S; Canha-Borges A; Oliveira MJ; Sarmento B; Castro F Small; 2024 Oct; 20(41):e2300666. PubMed ID: 36978237 [TBL] [Abstract][Full Text] [Related]
17. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155 [TBL] [Abstract][Full Text] [Related]
18. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Su YC; Burnouf PA; Chuang KH; Chen BM; Cheng TL; Roffler SR Nat Commun; 2017 Jun; 8():15507. PubMed ID: 28593948 [TBL] [Abstract][Full Text] [Related]
19. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Wang Z; Sau S; Alsaab HO; Iyer AK Nanomedicine; 2018 Jun; 14(4):1441-1454. PubMed ID: 29678787 [TBL] [Abstract][Full Text] [Related]
20. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy. Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]